NCT06029270 2026-03-18Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerNational Cancer Institute (NCI)Phase 2 Recruiting156 enrolled